ZGNX News and Press, Zogenix Inc. From 09/14/20

Ligand inks deal to acquire Taurus and xCella Biosciences Ligand Pharmaceuticals Inc. ( LGND ) reported that it has inked a deal to acquire two companies, xCella Biosciences Inc. and Taurus Biosciences. Both these companies are privately held and are expected to boost Ligand’s Omn...

Zogenix (NASDAQ: ZGNX ) announces positive results from a third Phase 3 clinical trial, Study 3, evaluating Fintepla (fenfluramine) for the treatment of seizures associated with Dravet syndrome, a rare and severe type of childhood epilepsy. The results were consistent with the results in...

Results corroborate highly statistically significant convulsive seizure reductions seen in earlier multinational Phase 3 studies of FINTEPLA in Dravet syndrome FINTEPLA at 0.7 mg/kg/day achieved a 64.8% greater reduction in mean monthly convulsive seizures compared to placebo (p<...

Shares of GW Pharmaceuticals (NASDAQ: GWPH) have been sliding since the company reported quarterly results that were arguably positive. Even though GW Pharmaceuticals reported second-quarter product sales that grew 70% year over year, its stock price has tumbled about 20% since announci...

Image source: The Motley Fool. Zogenix Inc   (NASDAQ: ZGNX) Q2 2020 Earnings Call Aug 5, 2020 , 4:30 p.m. ET Operator Continue reading

Zogenix, Inc. (ZGNX) Q2 2020 Earnings Conference Call August 05, 2020 4:30 PM ET Company Participants Brian Ritchie – Investor Relations Stephen Farr – Chief Executive Officer Michael Smith – Chief Financial Officer Ashish Sagrolikar – Chief Commerci...

Zogenix (NASDAQ: ZGNX ) : Q2 GAAP EPS of -$0.96 beats by $0.04 . More news on: Zogenix, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

FINTEPLA® (fenfluramine) in Dravet syndrome is now FDA approved and commercially launched in the U.S. More than 230 prescribers have already completed FINTEPLA REMS enrollment and certification FDA meeting scheduled in September to discuss planned sNDA for FINTEPLA in ...

Most cannabis-related companies have seen their stock prices tumble over the past few months, but a few have been more resilient. Although GW Pharma (NASDAQ: GWPH) might not be a pot stock in the traditional sense, sales of the company's cannabidiol (CBD)-based drug, Epidiolex, have been gro...

EMERYVILLE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and six months ended June 30, 2020, after the market close, and will...